Initiation: Potent anti-tumour vaccine effect
Imugene is progressing its gastric (stomach) cancer therapeutic vaccine, HER-Vaxx, into a Phase Ib/II. This aims to replicate and improve on the combination of two proven therapeutic antibodies, Herceptin and Perjeta (Roche), which significantly improves survival in breast cancer and may do so in gastric cancer. Global gastric cancer incidence is 934,000 cases with few current therapeutic options and low survival. In the HER-Vaxx Phase I, management observes that patient antibodies displayed potent anti-tumour activity with an immune response. Imugene has placed A$2.25m of shares and announced a share purchase plan to initiate Phase Ib/II, with the aim of progressing the study to gain a major pharma deal following Phase II data in the buoyant cancer immunotherapy area.Imugene is an immuno-oncology focused biopharmaceutical company developing HER2 +ve gastric and breast cancer vaccines. Co.'s primary product is HER-Vaxx, a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.